BIM is Big, page-8

Hi ds,
In theory, it could but I doubt whether that's the intention. I suspect that Venetoclax will represent the first generation of BH3-mimetric drugs. Its the breakthrough drug in the field of apoptosis in much the same way as Ipilimumab pioneered the world's first checkpoint inhibitor and represented a paradigm shift in immuno-oncology. Ipilimumab was a CTLA-4 inhibitor but has now been overtaken by drugs targeting PD-1 and PD-L1 pathways - Keytruda, Opdivo and Tecentriq.

My educated guess is that the collaborative team led by Doug Fairlie are researching second generation BH3-mimetric drugs. Australian scientists from WEHI and ONJCRI are world leaders in the field of apoptosis. FPP-Bim could potentially be far more effective because - as you say - 'it removes its dependency on a specific combination of proteins in a specific concentration'.

Bristol-Myers Squibb had first mover advantage with Ipilimumab and followed up with its PD-1 checkpoint inhibitor Opdivo. I suspect that Genentech will seek to consolidate its own first-mover advantage.

The excitement with FPP-Bim is magnified by the apparent synergy with the Myc inhibitor. Each is critically important in its own right but together, the tremendous potential for another paradigm shift in cancer treatment is palpable.

Of course, I'm joining together a lot of dot points from presentations and scientific papers which is where we miss a CEO. That said, the academic-biotech collaboration model embraced by Phylogica is world-class innovative thinking in creating the potential for therapeutic breakthroughs re: compare with CRUK Grand Challenge team concept.